Director at Hologic (HOLX) awarded 3,190 restricted stock units

Rhea-AI Filing Summary

Hologic director Stacey D. Stewart reported an equity grant of 3,190 restricted stock units on February 26, 2026. The award has no cash exercise price and will vest on the date of the 2027 Annual Meeting of Stockholders, then be settled in shares of common stock.

After this grant, Stewart directly holds 8,358 shares and units in total, including 3,436 restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stewart Stacey D.

(Last) (First) (Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		3,190(1)	A	(2)	8,358(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units which vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.

2. Restricted stock units are settled in shares of common stock on a one-for-one basis.

3. Includes 3,436 restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.

	/s/ Mark W. Irving, attorney-in-fact for Ms. Stewart	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Hologic (HOLX) director Stacey D. Stewart report in this Form 4?

Stacey D. Stewart reported receiving 3,190 restricted stock units as an equity award. These units represent future Hologic common shares and increase her total direct holdings to 8,358 shares and units, according to the filing’s reported post-transaction balance.

When do Stacey D. Stewart’s new Hologic restricted stock units vest?

The 3,190 new restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders. At that time, they are scheduled to be settled in shares of common stock on a one-for-one basis, as described in the footnotes.

How are Hologic restricted stock units settled for Stacey D. Stewart?

Hologic’s restricted stock units for Stacey D. Stewart are settled in common stock on a one-for-one basis. Once vested, each unit converts into one share of Hologic common stock, rather than requiring any cash payment or exercise price from the director.

How many Hologic shares and units does Stacey D. Stewart hold after this grant?

After the grant, Stacey D. Stewart holds 8,358 Hologic shares and units directly. This total includes 3,436 restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan, as specifically noted in the filing’s footnotes.

What portion of Stacey D. Stewart’s Hologic holdings are deferred restricted stock units?

The filing notes that 3,436 of Stacey D. Stewart’s holdings are restricted stock units with deferred settlement. These units will be settled in Hologic common stock at a later time under the company’s Deferred Equity Plan, rather than immediately upon vesting.